MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS

MoonLake Immunotherapeutics

Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.
Positive Phase 2 MIRA trial met primary endpoint HiSCR75 at week 12; sonelokimab showed highest clinical activity among tested therapies.
Completed randomization of 200 patients in Phase 2 ARGO PsA trial ahead of schedule; top-line 12-week data expected H1 Nov 2023.
R&D expenses $8.7M, G&A $4.5M for Q2 2023; no revenue (clinical-stage biotech).
Upcoming catalysts: MIRA 24-week data mid-Oct, ARGO 12-week data Nov, End of Phase 2 FDA meeting Dec 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MoonLake Immunotherapeutics reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Moonlake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001213900-23-065274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.